Fig. 2

Plasma apoE levels increased overtime in both studies. A In the GLP study, CS-6253 treatment significantly increased plasma apoE levels 48 h p.i. (p = 0.008). B In the DRF study, at 10 min and 2 h p.i. apoE decreased significantly (p < 0.001 and p = 0.020, respectively). Then, apoE significantly increased at 12 h, 24 h, 48 h p.i. (p < 0.001 for all 3) and accumulated treatment over time (p = 0.040). The values for the GLP study were shown as percent change from the first measurement point at 5 min p.i. on day 1 while the values for the DRF study were shown as percent change from the baseline measurement. The analysis was done using a mixed-effects model, with apoE modeled as a function of fixed effects including treatment (active compared with placebo), indicator variables for hours since injection (i.e., time of injection), and a linear variable for total time under study; a random intercept of subject was specified to model correlated outcomes arising from repeated measurements